Immunoreactive somatostatin-28(1-12) is increased in Huntington's disease.
Somatostatin-28(1-12) concentrations were measured in Huntington's disease (HD) postmortem tissue using a specific radioimmunoassay. Concentrations of immunoreactive somatostatin-28(1-12) were significantly increased in the caudate and putamen but were unchanged in cortical areas A9 and A17. Since somatostatin-28(1-12) terminates with the amino acids Arg-Glu-OH, we examined whether this dodecapeptide compound might exert a neurotoxic effect. Injections of somatostatin-28(1-12) into rat striatum showed no evidence of histologic damage.
Beal
M F
MF
Benoit
R
R
Bird
E D
ED
Martin
J B
JB
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D001923:Brain Chemistry; D003342:Corpus Striatum / Q000187:drug effects; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis* / Q000494:pharmacology; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000032:analysis* / Q000494:pharmacology; D053561:Somatostatin-28
D010446:Peptide Fragments; D013004:Somatostatin; D053561:Somatostatin-28; C037197:somatostatin 28-(1-12)